Synopsis
Synopsis
0
VMF
0
Canada
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers
1. 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
2. Amn 107
3. Amn-107
4. Amn107
5. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)
6. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate
7. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:1:2)
8. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (1:2:2)
9. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride, Hydrate (2:2:3)
10. Nilotinib
11. Nilotinib Dihydrochloride Dihydrate
12. Nilotinib Hydrochloride Anhydrous
13. Nilotinib Hydrochloride Dihydrate
14. Nilotinib Hydrochloride Hydrate
15. Nilotinib Hydrochloride Monohydrate
16. Nilotinib Hydrochloride Sesquihydrate
17. Tasigna
1. 923288-95-3
2. Nilotinib Hydrochloride Anhydrous
3. Nilotinib Hcl
4. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide Hydrochloride
5. Nilotinib (hydrochloride)
6. K37n7byx3x
7. 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrochloride
8. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, Hydrochloride (1:1)
9. Nilotinib (as Hydrochloride)
10. Unii-k37n7byx3x
11. Amn 107 Hydrochloride
12. Amn-107 Hcl
13. Schembl434496
14. Dtxsid60238968
15. Bcp29532
16. Hy-10159b
17. S5205
18. Ccg-270077
19. Nilotinib Hydrochloride [vandf]
20. Bn164657
21. Nilotinib Hydrochloride Monohydrate- Bio-x
22. Cs-0085192
23. Nilotinib Hydrochloride [orange Book]
24. Nilotinib Hydrochloride Anhydrous [who-dd]
25. Q27281888
26. Nilotinib Hcl;amn 107; Amn107; Amn-107; Nilotinib Hydrochloride Anhydrous
27. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamidehydrochloride
28. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide Hydrochloride
29. 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide Hydrochloride
Molecular Weight | 566.0 g/mol |
---|---|
Molecular Formula | C28H23ClF3N7O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 6 |
Exact Mass | 565.1604706 g/mol |
Monoisotopic Mass | 565.1604706 g/mol |
Topological Polar Surface Area | 97.6 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 817 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Danziten (nilotinib), an oral BCR-ABL kinase inhibitor, it is indicated for treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.
Lead Product(s): Nilotinib
Therapeutic Area: Oncology Brand Name: Danziten
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2024
AZURITY Wins FDA Approval for DANZITEN™ Tablets with No Mealtime Restrictions
Details : Danziten (nilotinib), an oral BCR-ABL kinase inhibitor, it is indicated for treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.
Brand Name : Danziten
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2024
Details:
XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.
Lead Product(s): Nilotinib
Therapeutic Area: Oncology Brand Name: XS003
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2024
Xspray Pharma’s XS003 Study Shows Lower Dose Bioavailability vs. Tasigna
Details : XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.
Brand Name : XS003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Details:
The agreement aims to to develop and market an anti-cancer drug, Tasigna (nilotinib), a transduction inhibitor, used for treatment of chronic myeloid leukemia.
Lead Product(s): Nilotinib
Therapeutic Area: Oncology Brand Name: Tasigna-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Aurobindo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 23, 2023
Aurobindo Pharma Arm Signs Pact with Medicines Patent Pool to Develop Anti-Cancer Drug
Details : The agreement aims to to develop and market an anti-cancer drug, Tasigna (nilotinib), a transduction inhibitor, used for treatment of chronic myeloid leukemia.
Brand Name : Tasigna-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 23, 2023
Details:
Proceeds from the financing will advance pipeline of optimized, low dose, orally delivered tyrosine kinase inhibitors including Nilotinib BE for the treatment of multiple neurodegenerative diseases.
Lead Product(s): Nilotinib
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 08, 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
Details : Proceeds from the financing will advance pipeline of optimized, low dose, orally delivered tyrosine kinase inhibitors including Nilotinib BE for the treatment of multiple neurodegenerative diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 08, 2021
Related Excipient Companies
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral
Dosage Form : Tablet
Grade : Oral
Application : Emulsifying Agents
Excipient Details : HDK N20 Pharma is used as a pharmaceutical emulsifying agent in tablets, capsules, syrups, and solutions.
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral
Dosage Form : Tablet
Grade : Oral
Brand Name : Titanium dioxide PRETIOX ...
Application : Coating Systems & Additives
Excipient Details : Titanium dioxide Pretiox AV01FG is used as a coloring and coating agent in oral solid dosage forms such as capsules, tablets, granules, and pellets.
Pharmacopoeia Ref : Fami-QS, Kosher, Halal, OHSAS ...
Technical Specs : Ti 59.95% and O 40.05%
Ingredient(s) : Titanium Dioxide
Dosage Form : Tablet
Grade : Oral
Excipients by Applications
Global Sales Information
Company :
Nilotinib HCl
Drug Cost (USD) : 375,995,128
Year : 2022
Prescribers : 3024
Prescriptions : 25750
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nilotinib HCl
Drug Cost (USD) : 352,216,339
Year : 2021
Prescribers : 3114
Prescriptions : 25986
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nilotinib HCl
Drug Cost (USD) : 339,500,199
Year : 2020
Prescribers : 3148
Prescriptions : 26481
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nilotinib HCl
Drug Cost (USD) : 318,637,020
Year : 2019
Prescribers : 3387
Prescriptions : 26746
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nilotinib HCl
Drug Cost (USD) : 346,488,392
Year : 2018
Prescribers : 3966
Prescriptions : 31475
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nilotinib HCl
Drug Cost (USD) : 348,087,826
Year : 2017
Prescribers : 4040
Prescriptions : 34606
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nilotinib HCl
Drug Cost (USD) : 307,612,237
Year : 2016
Prescribers : 3932
Prescriptions : 33201
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Nilotinib HCl
Drug Cost (USD) : 260,371,665
Year : 2015
Prescribers : 3648
Prescriptions : 30213
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
NILOTINIB HCL
Drug Cost (USD) : 204,569,988
Year : 2014
Prescribers : 3306
Prescriptions : 25711
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?